Furthermore, the patients’ susceptibility to DILI after supra-therapeutic drug exposures could be increased by liver inflammation due to CRS in COVID-19, attributing to ROS production via activation of NADPH oxidase (Maruf and O'Brien, 2014). The gene discussed is FMO5; the disease is COVID-19.